ArticleACS medicinal chemistry letters2022

Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent SETD2 Inhibitor for Clinical Studies.

Joshua S Alford et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.